SAN DIEGO–(BUSINESS WIRE)–Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that its recently completed Phase 3 clinical trial of CANDIN® (Purified Candida albicans Antigen), the Company’s investigational immunotherapeutic therapy for the treatment and resolution of common warts (Verruca vulgaris) met its primary endpoint as well as key secondary endpoints. The topline results of the trial were presented earlier this month at t
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
